Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • News & Views
  • Published:

Atrial fibrillation

Challenging the status quo: β-blockers for HF plus AF

Nature Reviews Cardiology volume 11, pages 690–692 (2014)Cite this article

Subjects

A new meta-analysis challenges the notion that β-blockers improve survival in patients with heart failure (HF) and concomintant atrial fibrillation (AF). These results should be interpreted with caution. Although the mortality reduction conferred by β-blockers was likely overestimated in the past, benefits should be expected in a sizeable proportion of patients with HF and AF.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

References

  1. Yancy, C. W. et al. 2013 ACCF/AHA guideline for the management of heart failure: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. J. Am. Coll. Cardiol. 62, e147–e239 (2013).

    Article  Google Scholar 

  2. O'Meara, E. et al. Mineralocorticoid receptor antagonists and cardiovascular mortality in patients with atrial fibrillation and left ventricular dysfunction: insights from the Atrial Fibrillation and Congestive Heart Failure Trial. Circ. Heart Fail. 5, 586–593 (2012).

    Article  CAS  Google Scholar 

  3. Al-Khatib, S. M. et al. Do patients with a left ventricular ejection fraction between 30% and 35% benefit from a primary prevention implantable cardioverter defibrillator? Int. J. Cardiol. 172, 253–254 (2014).

    Article  Google Scholar 

  4. Black, J. W. & Stephenson, J. S. Pharmacology of a new adrenergic beta-receptor-blocking compound (Nethalide). Lancet 2, 311–314 (1962).

    Article  CAS  Google Scholar 

  5. Kotecha, D. et al. Efficacy of beta blockers in patients with heart failure plus atrial fibrillation: an individual-patient data meta-analysis. Lancet http://dx.doi.org/10.1016/S0140-6736(14)61373-8.

  6. Kotecha, D. et al. Individual patient data meta-analysis of beta-blockers in heart failure: rationale and design. Syst. Rev. 2, 7 (2013).

    Article  Google Scholar 

  7. Roy, D. et al. Rhythm control versus rate control for atrial fibrillation and heart failure. N. Engl. J. Med. 358, 2667–2677 (2008).

    Article  CAS  Google Scholar 

  8. Talajic, M. et al. Maintenance of sinus rhythm and survival in patients with heart failure and atrial fibrillation. J. Am. Coll. Cardiol. 55, 1796–1802 (2010).

    Article  Google Scholar 

  9. Cadrin-Tourigny, J. et al. Efficacy of amiodarone in patients with atrial fibrillation with and without left ventricular dysfunction: a pooled analysis of AFFIRM and AF-CHF trials. J. Cardiovasc. Electrophysiol. http://dx.doi.org/10.1111/jce.12535.

  10. Andrade, J. et al. Baseline heart rate and adverse outcomes in patients with atrial fibrillation: a combined AFFIRM and AF-CHF substudy. Can. J. Cardiol. 28, S271–S272 (2012).

    Article  Google Scholar 

Download references

Acknowledgements

P.K. is supported by a Canada Research Chair in Electrophysiology and Adult Congenital Heart Disease.

Author information

Authors and Affiliations

  1. Electrophysiology Service and Research Center, Montreal Heart Institute, Université de Montréal, 5000 Bélanger Street, Montréal, H1T 1C8, Canada

    Paul Khairy & Denis Roy

Authors
  1. Paul Khairy
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Denis Roy
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Paul Khairy.

Ethics declarations

Competing interests

The authors declare no competing financial interests.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Khairy, P., Roy, D. Challenging the status quo: β-blockers for HF plus AF. Nat Rev Cardiol 11, 690–692 (2014). https://doi.org/10.1038/nrcardio.2014.166

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/nrcardio.2014.166

This article is cited by

Search

Advanced search

Quick links

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing